Canakinumab

Research use only, not for human use.

Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively.

Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin.

Canakinumab (0-7 nM) dose dependently represses IL-6 production in marmoset peripheral blood mononuclear cells with IC50s of 43.6 and 40.8 pM for human and marmoset IL-1β.Canakinumab effectively competes with IL-1RI and IL-1RII for binding to IL-1b.

——

——

Apoptosis

IL Receptor

IL Receptor

——

——

914613-48-2

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years